SEARCH

SEARCH BY CITATION

References

  • 1
    Lombardi M, Cerrai T, Geatti S et al. Results of a national epidemiological investigation on HCV infection among dialysis patients. J Nephrol 1999; 12: 3227.
  • 2
    Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 4451.
  • 3
    Jadoul M, Cornu C, Van Ypersele de Strihou Ch and The Universitaries Cliniques St-Luc (UCL) Collaborative Group. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. Kidney Int 1998; 53: 10225.
  • 4
    Schneeberger PM, Keur I, van der Vliet W et al. Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36: 17115.
  • 5
    Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002; 15: 16271.
  • 6
    Pinto dos Santos J, Loureiro A, Cendoroglo Neto M, Pereira BJG. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 201722.
  • 7
    Todorov V, Boneva R, Ilieva P, Doichinova T, Donchev M. High prevalence of hepatitis C virus infection in one dialysis center in Bulgaria. Nephron 1998; 79: 2223[letter].
  • 8
    Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs 2000; 23: 1818.
  • 9
    Covic A, Iancu L, Apetrei C et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14: 405.
  • 10
    Sayiner AA, Zeytinoglu A, Ozkahya M et al. HCV infection in haemodialysis and CAPD patients. Nephrol Dial Transplant 1998; 1: 2567[letter].
  • 11
    Hassan AA, Khalil R. Hepatitis C in dialysis patients in Egypt: Relationship to dialysis duration, blood transfusion, and liver disease. Saudi J Kidney Transplant 2000; 11: 725.
  • 12
    Yilmaz ME, Kara IH, Sari Y, Duzen S, Usul Y, Isikoglu B. Seroprevalence and risk factors of HCV in dialysis patients in a University hemodialysis center of Southeast Anatolia, Turkey. Dial Transplant 2001; 30: 74855.
  • 13
    Jaiswal SP, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalence of hepatitis viruses among chronic renal failure patients on hemodialysis in central India. Dial Transplant 2002; 31: 23440.
  • 14
    Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002; 57: 3715.
  • 15
    Marcelli D, Stanhard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patients mortality with adjustement for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50: 10138.
  • 16
    Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 939.
  • 17
    Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 46: 50411.
  • 18
    Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896902.
  • 19
    Espinosa M, Martin-Malo A, Alvarez de Lara M, Alijama P. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 166974.
  • 20
    Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interpheron alpha in kidney transplant recipients. Transplantation 1995; 59: 142631.
  • 21
    Magnone M, Holley JL, Shapiro R et al. Interferon-alpha induced acute renal allograft rejection. Transplantation 1995; 59: 106870.
  • 22
    Thervet E, Pol S, Legendre Ch, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 1994; 58: 6258.
  • 23
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 5126.
  • 24
    Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 25763.
  • 25
    Legendre C, Garrigue V, Le Biham C et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 66770.
  • 26
    Gentil M, Rocha JL, Rodriguez-Algarra G et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 245560.
  • 27
    Hanafusa T, Ichikawa Y, Kishikawa H et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 4716.
  • 28
    Pereira BJG, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799805.
  • 29
    Bucci JR, Matsumoto CS, Swanson SJ et al. Donor C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 297482.
  • 30
    Stehman-Breen CP, Psaty BM, Emerson S et al. Association of hepatitis C virus infection with mortality and graft survival in kidney–pancreas transplant recipients. Transplantation 1997; 64: 2816.
  • 31
    Gürsoy M, Gur G, Arsian H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepatol 2001; 8: 707.
  • 32
    Ellis ME, Alfurayh O, Halim MA et al. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 1993; 18: 2106.
  • 33
    Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 15079.
  • 34
    Duarte R, Huraib S, Saed R et al. Interpheron-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995; 25: 405.
  • 35
    Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 14128.
  • 36
    Ozylkan E, Simsek H, Uzunalimoglu B, Telatar H. Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure. Nephron 1995; 71: 1569.
  • 37
    Okuda K, Hayashi H, Yokozeki K, Kondo T, Kashima T, Irie Y. Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on small series. J Gastroenterol Hepatol 1995; 10: 61626.
  • 38
    Pol S, Thiers V, Carnot F et al. Effectiveness and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 5861.
  • 39
    Raptopoulou-Gigi M, Spaia S, Garifallos A et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 18347.
  • 40
    Simsek H. Interferon-alpha treatment of haemodialysis patients with chronic viral hepatitis and its impact on kidney transplantation. Nephrol Dial Transplant 1996; 11: 9123[letter].
  • 41
    Fernandez JL, Rendo P, Del Pino N et al. A double-blind controlled trial or recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepatol 1997; 4: 1139.
  • 42
    Izopet J, Rostaing L, Mouission F et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 16147.
  • 43
    Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng IKP. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 14149.
  • 44
    Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998; 80: 516.
  • 45
    Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 1414.
  • 46
    Tokumoto T, Tanabe K, Ishikawa N et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31: 28879.
  • 47
    Huraib S, Tanimu D, Romeh SA et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34: 5560.
  • 48
    Campistol JM, Esforzado N, Martinez J et al. Efficacy and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 27049.
  • 49
    Espinosa M, Rodriguez M, Martin-Malo A et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55: 2206.
  • 50
    Casanovas-Taltavull T, Baliellas C, Benasco C et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 11707.
  • 51
    Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 43540.
  • 52
    Hanrotel C, Toupance O, Lavaud S et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 1206.
  • 53
    Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 101723.
  • 54
    Dincer D, Besisik F, Oguz F et al. Genes of major histocompatibility complex class II influence chronic hepatitis C hepatitis treatment with interferon in hemodialysis patients. Int J Artif Organs 2001; 24: 2124.
  • 55
    Tan ACITL, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C. results of a pilot study. Nephrol Dial Transplant 2001; 16: 1935[letter].
  • 56
    Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2001; 16: 1729[letter].
  • 57
    Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection – a pilot study. J Viral Hepatol 2001; 8: 28792.
  • 58
    Poynard T, Conn HO. The retrieval of randomised clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985; 6: 2719.
  • 59
    Thevenot T, Regimbeau C, Ratziou V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients. J Viral Hepat 2001; 8: 4862.
  • 60
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 61
    Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114S120.
  • 62
    Fabrizi F, Poordad F, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 310.
  • 63
    Badalamenti S, Catania A, Lunghi G et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus- positive patients: only coincidental phenomena ? Am J Kidney Dis 2003; 42: 14350.
  • 64
    Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of IFN alpha-2b in chronic hepatitis C virus undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 23448.
  • 65
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. a randomised trial. Lancet 2001; 358: 95865.
  • 66
    McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 67
    Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321: 15016.
  • 68
    Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. effects of dose and duration. Hepatology 1996; 24: 77889.
  • 69
    Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991; 44: 12739.